Prevention strategies to identify LASA errors: building and sustaining a culture of patient safety
| Autor: | Eduardo L. Mariño, Carlos Figueiredo-Escribá, M. Ángeles Piñero-López, Cecilia Fernández Lastra, Irene Lizano-Díez, Pilar Modamio |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Seguretat dels pacients
Safety Management medicine.medical_specialty Debate Look-alike sound-alike Drug Prescriptions 030226 pharmacology & pharmacy Health informatics Health administration Therapeutic equivalency in drugs 03 medical and health sciences Patient safety 0302 clinical medicine Equivalència terapèutica dels medicaments Medication errors Outpatients Drug prescribing medicine Humans 030212 general & internal medicine Medical prescription Drug safety Patients safety Inpatients business.industry Health Policy Nursing research Public health Drug labeling lcsh:Public aspects of medicine Drugs International health lcsh:RA1-1270 Public relations Name confusion Prescripció de medicaments business Medicaments |
| Zdroj: | BMC Health Services Research, Vol 20, Iss 1, Pp 1-5 (2020) BMC Health Services Research Dipòsit Digital de la UB Universidad de Barcelona |
| ISSN: | 1472-6963 |
| Popis: | Background Potential look-alike, sound-alike (LASA) errors in outpatient and inpatient prescriptions have been widely described worldwide. However, most strategies of reducing drug name confusion have been only focused on the processes of prescribing and dispensing, often following local rules. Main text An illustrative recent example about this topic is given: the antidepressant Brintellix® (vortioxetine) (Takeda Pharmaceuticals USA, Inc.) and the antiplatelet medication Brilinta® (ticagrelor) (AstraZeneca LP). Revision of the initiatives that are currently applied to prevent potential LASA errors in different countries around the world and debate about the emerging strategies that could be implemented in short and mid-term. At present, a common policy worldwide on the authorization of unique names for innovative medicines does not exist. The implication of authorities in topdown strategies and the importance of developing an international health policy on the authorization of unique names for innovative medicines are highlighted in the following piece of opinion. Conclusions Building and sustaining a culture of patient safety should be considered as a global top-down strategy which involved all the elements in the system (regulatory bodies, manufacturers and suppliers). The precedent established by the FDA in prevention strategies to identify and avoid LASA errors has been extremely important and should lead to international discussion. Coordinated international efforts are urgently needed in this area for the sake of patients’ safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |